A small-molecule inhibitor of hepatitis C virus infectivity
| Autor: | Matthew Paulson, Eda Canales, Kerim Babaoglu, Caroline O. Bush, William E. Delaney, Justin Golde, Rudolf K. F. Beran, Lazerwith Scott E, Brian Reid, Weidong Zhong, Morganelli Philip Anthony, Maria Pokrovskii, Michael O'neil Hanrahan Clarke, Nikos Pagratis, Saito Roland D |
|---|---|
| Rok vydání: | 2013 |
| Předmět: |
Hepatitis C virus
Hepacivirus Viral Nonstructural Proteins medicine.disease_cause Virus Replication Antiviral Agents Cell Line Viral envelope Drug Resistance Viral medicine Humans Pharmacology (medical) Pharmacology Infectivity biology virus diseases Hepatitis C medicine.disease biology.organism_classification Virology Viral Breakthrough digestive system diseases NS2-3 protease Infectious Diseases Viral replication Immunology |
| Zdroj: | Antimicrobial agents and chemotherapy. 58(1) |
| ISSN: | 1098-6596 |
| Popis: | One of the most challenging goals of hepatitis C virus (HCV) research is to develop well-tolerated regimens with high cure rates across a variety of patient populations. Such a regimen will likely require a combination of at least two distinct direct-acting antivirals (DAAs). Combining two or more DAAs with different resistance profiles increases the number of mutations required for viral breakthrough. Currently, most DAAs inhibit HCV replication. We recently reported that the combination of two distinct classes of HCV inhibitors, entry inhibitors and replication inhibitors, prolonged reductions in extracellular HCV in persistently infected cells. We therefore sought to identify new inhibitors targeting aspects of the HCV replication cycle other than RNA replication. We report here the discovery of the first small-molecule HCV infectivity inhibitor, GS-563253, also called HCV infectivity inhibitor 1 (HCV II-1). HCV II-1 is a substituted tetrahydroquinoline that selectively inhibits genotype 1 and 2 HCVs with low-nanomolar 50% effective concentrations. It was identified through a high-throughput screen and subsequent chemical optimization. HCV II-1 only permits the production and release of noninfectious HCV particles from cells. Moreover, infectious HCV is rapidly inactivated in its presence. HCV II-1 resistance mutations map to HCV E2. In addition, HCV-II prevents HCV endosomal fusion, suggesting that it either locks the viral envelope in its prefusion state or promotes a viral envelope conformation change incapable of fusion. Importantly, the discovery of HCV II-1 opens up a new class of HCV inhibitors that prolong viral suppression by HCV replication inhibitors in persistently infected cell cultures. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|